Manish Kadian, MD
Nephrology · Columbia, SCNPI 1528210887
Payments from drug & device makers
Across 123 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$419
- Fresenius USA Marketing, Inc.$382
- GSK$194
- Novartis$173
- Mallinckrodt Hospital Products Inc.$157
- Akebia Therapeutics Inc$136
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,35895%
- Education$1285%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 22 | $419 |
| Fresenius USA Marketing, Inc. | 12 | $382 |
| GSK | 13 | $194 |
| Novartis | 10 | $173 |
| Mallinckrodt Hospital Products Inc. | 6 | $157 |
| Akebia Therapeutics Inc | 8 | $136 |
| Vifor Pharma, Inc. | 7 | $133 |
| AstraZeneca(2 entities) | 7 | $114 |
| Nxstage Medical, Inc. | 1 | $80 |
| Calliditas Therapeutics US Inc. | 4 | $79 |
| Aurinia Pharma U.S., Inc. | 3 | $74 |
| Travere Therapeutics, Inc. | 4 | $74 |
| Otsuka America Pharmaceutical, Inc. | 4 | $72 |
| Novo Nordisk | 3 | $68 |
| Bayer | 4 | $63 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $53 |
| Mallinckrodt Enterprises LLC | 4 | $47 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Veloxis Pharmaceuticals, Inc. | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $19 |
| Sanofi | 1 | $17 |
| VBI Vaccine (delaware) Inc. | 1 | $17 |
| Ascendis Pharma Endocrinology Inc | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Biomerieux Inc | 1 | $9 |
How this compares
$2,486 in reported general payments places this provider in the 50th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 50 | $216,030 |
| ProcritEpoetin Alfa | 34 | $32,494 |
| FarxigaDapagliflozin Propanediol | 30 | $24,445 |
| Sevelamer Carbonate | 43 | $12,312 |
| LokelmaSodium Zirconium Cyclosilicate | 14 | $12,133 |
| RetacritEpoetin Alfa-Epbx | 32 | $9,355 |
| Midodrine Hcl | 13 | $3,043 |
| Cefpodoxime Proxetil | 14 | $1,333 |
| Nifedipine ErNifedipine | 29 | $691 |
| Bumetanide | 17 | $656 |
| Valsartan | 39 | $633 |
| Amlodipine Besylate | 75 | $378 |
| Prednisone | 57 | $374 |
| Hydralazine Hcl | 35 | $341 |
| Losartan Potassium | 37 | $317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $382 | $216,03050 claims |
| AstraZenecaFarxiga, Lokelma | $114 | $36,57844 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $22 | $63339 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 180 nephrology providers in South Carolina.
Other nephrology in Columbia
- Asha BaileyColumbia$724K
- Thomas PowellColumbia$704K
- Howard LiflandColumbia$261K
- Jennifer OthersenColumbia$48K
- Renee EllisColumbia$40K
- David ShureColumbia$19K
- Niall McLaughlinColumbia$15K
- Roy MathewColumbia$10K
- Thomas WheelerColumbia$9K
- Rajeev ShenoyColumbia$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.